AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
EBOS Group Ltd (ASX:EBO)
36.16 AUD
+0.570 1.602%Sponsored Reports
Loading...
| Previous Close (in AUD) | 35.59 |
|---|---|
| Change | +0.570 1.602% |
| 52 W H/L (in AUD) | 37.595/28.037 |
| EBITDA (in AUD) | 526.207M |
| PE Ratio | 27.22 |
| Volume | 272185 |
| Diluted Eps TTM | 1.30 |
| Total Assets (in AUD) | 7368.949M |
|---|---|
| Total Liabilities (in AUD) | 4726.358M |
| Revenue TTM (in AUD) | 12597.976M |
| Cash (in AUD) | 236.979M |
| Market Cap (in AUD) | 7,176.880 M |
| Revenue Per Share TTM | 65.161 |
| Gross Profit TTM (in AUD) | 1609.532M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Ebos Group Ltd
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. In addition, the company supplies health and wellness products to public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; and provides pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers allografts solutions; healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.
Employees: 5200
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. John Cullity | Chief Exec. Officer | NA |
| 2. | Mr. Leonard Hansen | CFO & Chief Accountant | NA |
| 3. | Ms. Andrea Bell | Chief Information Officer | NA |
| 4. | Martin Krauskopf | Exec. GM of Strategy, Mergers & Acquisitions and GM of Investor Relations | NA |
| 5. | Ms. Janelle Cain | Gen. Counsel | NA |
| 6. | Ms. Jacinta McCarthy | Group Gen. Mang. of HR | NA |
| 7. | Mr. Simon Bunde | Exec. Gen. Mang. of Strategic Operations, ESG & Innovation | NA |
| 8. | Ms. Julie Dillon | Chief Exec. Officer of Animal Care | NA |
| 9. | Mr. Matthew Muscio | Chief Exec. Officer of Medical Technology | NA |
| 10. | Mr. Brett Barons | Chief Exec. Officer of Symbion | NA |
Peers
Sector: Healthcare
Industry: Medical Distribution
| Company | Change (AUD) | Price (AUD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
SIG
Sigma Pharmaceuticals Ltd |
-0.020 0.669% | 2.97 | 0.000 | 51.814 | 9.966 | 41.471 | 7.185 | 628.498 |
|
PGC
Paragon Care Ltd |
+0.010 2.740% | 0.37 | 36.500 | 5.984 | 0.179 | 1.916 | 0.188 | 11.077 |
|
CYC
Cyclopharm Ltd |
+0.010 1.099% | 0.915 | 0.000 | 116.279 | 3.648 | 2.367 | 3.223 | -24.571 |
Income Statement
(Currency in AUD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Income Before Tax | 406.389M | 327.368M | 282.603M | 246.235M | 201.941M |
| Minority Interest | -10.961M | 0.629M | -5.321M | -4.073M | -3.071M |
| Net Income | 275.735M | 224.642M | 199.094M | 173.946M | 173.946M |
| Selling General Administrative | 578.276M | 467.055M | 382.434M | 347.691M | 357.611M |
| Gross Profit | 1698.915M | 1380.713M | 1066.337M | 987.111M | 846.265M |
| Reconciled Depreciation | 135.797M | 90.777M | 78.054M | 78.29M | 33.544M |
| Ebit | 495.059M | 365.488M | 313.513M | 276.318M | 233.151M |
| Ebitda | 630.856M | 456.266M | 391.568M | 354.608M | 266.695M |
| Depreciation And Amortization | 135.797M | 90.777M | 78.054M | 78.29M | 33.544M |
| Operating Income | 483.204M | 382.215M | 308.564M | 277.979M | 233.151M |
| Other Operating Expenses | 10402.475M | 9496.654M | 8072.804M | 7684.126M | 7012.379M |
| Interest Expense | 73.793M | 25.439M | 22.178M | 25.321M | 28.522M |
| Tax Provision | 119.693M | 103.354M | 84.85M | 68.541M | 56.288M |
| Interest Income | 9.296M | 3.062M | 0.766M | 30.396M | 25.334M |
| Net Interest Income | -76.789M | -31.805M | -21.412M | -23.836M | -26.506M |
| Income Tax Expense | 119.693M | 103.354M | 84.85M | 73.361M | 58.891M |
| Total Revenue | 13317.446M | 11901.673M | 9888.134M | 9381.933M | 7250.847M |
| Total Operating Expenses | 1199.918M | 985.253M | 748.812M | 704.388M | 607.797M |
| Cost Of Revenue | 11618.531M | 10520.96M | 8821.796M | 8394.822M | 6404.583M |
| Total Other Income Expense Net | -15.819M | -36.287M | -5.232M | -3.955M | -31.211M |
| Net Income From Continuing Ops | 286.696M | 224.014M | 197.753M | 172.874M | 143.05M |
| Net Income Applicable To Common Shares | 253.373M | 202.605M | 185.297M | 162.518M | 137.7M |
Balance Sheet
(Currency in AUD)| Breakdown | 30-06-2024 | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 |
|---|---|---|---|---|---|
| Total Assets | 7368.949M | 7005.151M | 6945.942M | 4243.857M | 4010.264M |
| Intangible Assets | 579.007M | 560.74M | 267.563M | 174.539M | 177.986M |
| Other Current Assets | 65.893M | 68.808M | 58.271M | 15.508M | 15.809M |
| Total Liab | 4726.358M | 4498.501M | 4560.36M | 2733.486M | 2607.21M |
| Total Stockholder Equity | 2678.113M | 2649.246M | 2511.156M | 1516.089M | 1407.414M |
| Other Current Liab | 337.632M | 620.429M | 827.05M | 438.54M | 503.063M |
| Common Stock | 2116.707M | 2056.658M | 2007.498M | 1067.601M | 1029.098M |
| Capital Stock | 2116.707M | 2056.658M | 2007.498M | 1067.601M | 1029.098M |
| Retained Earnings | 574.13M | 608.802M | 534.057M | 465.728M | 398.172M |
| Good Will | 2259.281M | 2150.798M | 2372.809M | 1073.75M | 1037.807M |
| Other Assets | - | 208.597M | 182.165M | 141.836M | 0M |
| Cash | 236.979M | 230.587M | 573.585M | 181.533M | 261.991M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 3413.894M | 2892.647M | 2784.821M | 2017.813M | 1891.886M |
| Current Deferred Revenue | - | -98.615M | -416.9M | -163.866M | -299.733M |
| Net Debt | 1558.217M | 1165.586M | 1253.232M | 549.448M | 603.88M |
| Short Term Debt | 899.199M | 100.409M | 414.84M | 164.541M | 300.511M |
| Short Long Term Debt | 836.656M | 45.842M | 367.576M | 125.325M | 264.284M |
| Short Long Term Debt Total | 1795.196M | 1396.173M | 1826.817M | 730.981M | 865.871M |
| Other Stockholder Equity | 0M | -2657.776M | -2534.048M | -1530.975M | -1425.067M |
| Property Plant Equipment | - | 660.675M | 576.977M | 464.938M | 402.418M |
| Total Current Assets | 3258.514M | 3272.257M | 3397.999M | 2282.847M | 2161.869M |
| Long Term Investments | 61.67M | 58.385M | 65.858M | 60.767M | 61.283M |
| Short Term Investments | - | 14.734M | 17.016M | -0.093M | -0.095M |
| Net Receivables | 1633.046M | 1629.694M | 1524.261M | 1242.612M | 1094.495M |
| Long Term Debt | 513.66M | 1018.991M | 1160.061M | 347.658M | 324.916M |
| Inventory | 1322.596M | 1343.168M | 1241.882M | 843.194M | 789.574M |
| Accounts Payable | 2177.063M | 2270.424M | 1959.831M | 1578.599M | 1388.046M |
| Accumulated Other Comprehensive Income | -12.724M | -16.214M | -30.398M | -17.24M | -19.856M |
| Non Currrent Assets Other | 37.673M | 19.167M | 1.508M | 0.032M | 0.35M |
| Non Current Assets Total | 4110.435M | 3732.894M | 3547.943M | 1961.01M | 1848.396M |
| Capital Lease Obligations | 444.879M | 331.34M | 299.18M | 257.998M | 253.822M |
| Long Term Debt Total | - | - | - | 527.186M | 528.216M |
Cash Flow
(Currency in AUD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Investments | -167.88M | -7.896M | -0.497M | -3.551M | -0.11M |
| Total Cashflows From Investing Activities | -154.265M | -1396.197M | -113.763M | -73.331M | -120.053M |
| Total Cash From Financing Activities | -595.42M | 1664.953M | -279.334M | -79.976M | 17.122M |
| Net Income | 274.94M | 223.979M | 198.789M | 173.678M | 144.068M |
| Change In Cash | -332.387M | 386.255M | -81.471M | 83.654M | 17.526M |
| Begin Period Cash Flow | 562.973M | 187.33M | 263.004M | 178.337M | 156.8M |
| End Period Cash Flow | 230.587M | 573.585M | 181.533M | 261.991M | 174.325M |
| Total Cash From Operating Activities | 424.69M | 274.977M | 320.034M | 244.93M | 124.025M |
| Depreciation | 135.406M | 90.509M | 77.934M | 78.169M | 33.544M |
| Other Cashflows From Investing Activities | - | - | -31.503M | -44.05M | -85.852M |
| Dividends Paid | -191.24M | -170.873M | -134.292M | -119.698M | 104.553M |
| Change To Inventory | -141.35M | -352.89M | -50.489M | -15.156M | -188.435M |
| Sale Purchase Of Stock | 26.054M | 1287.158M | 53.293M | 43.487M | 168.175M |
| Other Cashflows From Financing Activities | -53.306M | -45.394M | -37.887M | -34.204M | 24.144M |
| Capital Expenditures | 107.032M | 99.384M | 88.385M | 31.34M | 35.783M |
| Change In Working Capital | -275.287M | -593.441M | -194.151M | -148.516M | 3.321M |
| Other Non Cash Items | 14.344M | -39.512M | 43.312M | -6.916M | -177.611M |
| Free Cash Flow | 317.658M | 175.593M | 231.649M | 213.59M | 88.242M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard International Stock Index-Total Intl Stock Indx | 4 years ago | 1426138 |
| 2. | Fidelity International Small Cap Fund | 4 years ago | 747510 |
| 3. | Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 4 years ago | 592143 |
| 4. | Variable Insurance Products Fund-Overseas Portfolio | 4 years ago | 469936 |
| 5. | DFA International Core Equity Portfolio | 4 years ago | 322374 |
| 6. | Fidelity Series International Small Cap Fund | 4 years ago | 336913 |
| 7. | Fidelity International Discovery Fund | 4 years ago | 1521700 |
| 8. | Fidelity Overseas Fund (US) | 4 years ago | 2243701 |
| 9. | Fidelity Pacific Basin Fund | 4 years ago | 416179 |
| 10. | Fidelity Series Intrinsic Opportunities Fund | 4 years ago | 495517 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...